Literature DB >> 2402741

Hereditary dysfunctional protein C molecules (type II): assay characterization and proposed classification.

R A Marlar1, D M Adcock, R M Madden.   

Abstract

Protein C (PC) deficiency is among the increasing number of recognized causes of hereditary thrombotic disease. Two types of PC deficiency have been described: 1) Type I, which is characterized by a concomitant decrease in PC activity and antigen, and 2) Type II, characterized by disproportionately low activity compared to antigen (i.e. a dysfunctional molecule). To date, only a small number of Type II patients have been described. This study was undertaken to evaluate a number of dysfunctional PC molecules by comparing PC clotting and amidolytic activities with antigen levels. For these studies, an automated PTT-based clotting PC assay was developed. This assay was sensitive to 1% of a normal plasma pool, specific, accurate, and reproducible (+/- 12%). A good correlation (r = 0.918) of the clotting activity to antigen was found in normal individuals and Type I heterozygous and homozygous patients. To classify Type II PC deficient patients, the antigen, amidolytic and clotting PC levels were compared in ten affected families. The clotting activities were decreased in all affected members, whereas the antigen levels were within the normal limits. In four of the 10 families, the amidolytic activity was normal and similar to the antigen levels. This suggests that in certain families, defects in the PC molecule occur in regions not associated with amidolytic functions. From these studies, the molecular basis of Type II PC deficiency is varied and complex, involving different functional domains of the PC molecule. Therefore, we have suggested a nomenclature algorithm for Type II PC deficiency based on the location of the defect within the specific domains of the PC molecule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402741

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population.

Authors:  Hee-Jin Kim; Ja-Young Seo; Ki-O Lee; Sung-Hwan Bang; Seung-Tae Lee; Chang-Seok Ki; Jong-Won Kim; Chul Won Jung; Duk-Kyung Kim; Sun-Hee Kim
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

3.  Laboratory Limitations of Excluding Hereditary Protein C Deficiency by Chromogenic Assay: Discrepancies of Phenotype and Genotype.

Authors:  Holger Seidel; Bianca Haracska; Jennifer Naumann; Philipp Westhofen; Moritz Sebastian Hass; Johannes Philipp Kruppenbacher
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

4.  Deficiencies of the Natural Anticoagulants - Novel Clinical Laboratory Aspects of Thrombophilia Testing.

Authors:  Zsuzsanna Bereczky; Réka Gindele; Marianna Speker; Judit Kállai
Journal:  EJIFCC       Date:  2016-04-20

5.  Comparison of clot-based and chromogenic assay for the determination of protein c activity.

Authors:  Tariq M Roshan; Nancy Stein; Xiu Y Jiang
Journal:  Blood Coagul Fibrinolysis       Date:  2019-06       Impact factor: 1.276

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.